Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more
Beam Therapeutics Inc (BEAM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.067x
Based on the latest financial reports, Beam Therapeutics Inc (BEAM) has a cash flow conversion efficiency ratio of -0.067x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-83.29 Million) by net assets ($1.24 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beam Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Beam Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Beam Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beam Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Universal Microwave Technology
TWO:3491
|
-0.012x |
|
Shenzhen Senior Technology Material Co Ltd
SHE:300568
|
0.012x |
|
First Merchants Corporation
NASDAQ:FRME
|
0.033x |
|
China National Building Material Company Limited
F:D1Y
|
0.022x |
|
Zhongyuan Bank Co., Ltd.
PINK:ZNNGY
|
N/A |
|
Seadrill Limited
NYSE:SDRL
|
-0.014x |
|
Hanesbrands Inc
NYSE:HBI
|
0.062x |
|
DKSH Holding AG
SW:DKSH
|
0.100x |
Annual Cash Flow Conversion Efficiency for Beam Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Beam Therapeutics Inc from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.24 Billion | $-345.10 Million | -0.279x | +41.13% |
| 2024-12-31 | $733.54 Million | $-347.25 Million | -0.473x | -211.37% |
| 2023-12-31 | $981.33 Million | $-149.19 Million | -0.152x | -595.02% |
| 2022-12-31 | $733.47 Million | $22.53 Million | 0.031x | +138.32% |
| 2021-12-31 | $826.74 Million | $-66.27 Million | -0.080x | +79.44% |
| 2020-12-31 | $245.56 Million | $-95.74 Million | -0.390x | +45.34% |
| 2019-12-31 | $100.94 Million | $-72.00 Million | -0.713x | -370.99% |
| 2018-12-31 | $134.03 Million | $-20.30 Million | -0.151x | -123.40% |
| 2017-12-31 | $-4.18 Million | $-2.71 Million | 0.647x | -- |